Previous 10 | Next 10 |
2024-05-21 06:51:13 ET More on AbbVie, Alvotech, etc. AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript) Teva Pharmaceutical: 6 Takeaways Fr...
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira ® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvote...
2024-05-16 11:01:24 ET Billionaire Larry Robbins' Glenview Capital Management took a stake in Broadcom ( NASDAQ: AVGO ), exited its position in Intel ( NASDAQ: INTC ), and substantially added to holdings in health insurers in Q1 2024, among other changes.... Read the f...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is le...
2024-05-14 14:35:08 ET Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference May 14, 2024, 11:40 AM ET Company Participants Jason Gerberry - Managing Director, US Specialty Pharma and Smid Cap Biotech Richard Francis - President &a...
2024-05-09 08:15:00 ET Summary Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00. The company reported strong first-quarter results, with increased revenue and growth in key metrics. Teva has a positive business outlook for 2024, w...
2024-05-09 02:19:50 ET Summary Teva's Q1 earnings show continued momentum, with a 5% increase in total revenue and a jump in gross profit. The Company's blockbuster drugs, Austedo and Ajovy, continue to show robust growth and contribute to the company's revenue. TEVA's current...
2024-05-08 14:00:14 ET Image source: The Motley Fool. Teva Pharmaceutical Industries (NYSE: TEVA) Q1 2024 Earnings Call May 08, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Teva Pharmaceutical Industries (TEVA) Q1 202...
2024-05-08 11:32:14 ET Teva Pharmaceutical Industries Limited (TEVA) Q1 2024 Earnings Conference Call May 08, 2024, 08:00 AM ET Company Participants Ran Meir - Head, Investor Relations Richard Francis - Chief Executive Officer Eric Hughes - Head, R&D & Ch...
2024-05-08 10:13:13 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited 2024 Q1 - Results - Earnings Call Presentation Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportu...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes 1 Sub-analysis explorin...